Endocrinologic and Metabolic Drugs Advisory Committee; Amendment of Notice, 64346 [2012-25741]
Download as PDF
<![CDATA[
64346
Federal Register / Vol. 77, No. 203 / Friday, October 19, 2012 / Notices
clearly address the following sections of
the CFRs: § 418.52, § 418.54(e)(2),
§ 418.56(a), § 418.56(d), § 418.56(e),
§ 418.58, § 418.58(a)(2), § 418.58(c)(2),
§ 418.58(d)(1), § 418.60(b)(2)(ii),
§ 418.62(b), § 418.62(c), § 418.64(a)(1–3),
§ 418.64(b)(1), § 418.64(d)(3)(iv),
§ 418.72, § 418.76(a)(1), § 418.76(b)(3)(i),
§ 418.76(c), § 418.76(e), § 418.76(h)(1),
§ 418.76(j)(2), § 418.76(k), § 418.76(k)(2),
§ 418.100(b), § 418.100(c)(2),
§ 418.100(f)(1)(i), § 418.100(g)(3),
§ 418.104(d), § 418.104(f),
§ 418.106(b)(1), § 418.106(c)(1),
§ 418.106(e)(1), § 418.108(c)(3),
§ 418.110(a), § 418.110(c)(1)(i),
§ 418.110(c)(1)(ii), § 418.110(e),
§ 418.110(e)(2), § 418.110(f)(1),
§ 418.110(f)(3)(iv), § 418.110(f)(3)(vi),
§ 418.112(f), and § 418.116(b)(2).
B. Term of Approval
Based on the review and observations
described in section III of this final
notice, we have determined that CHAP’s
accreditation program for hospices meet
or exceed our requirements. Therefore,
we approve CHAP as a national
accreditation organization for hospices
that request participation in the
Medicare program, effective November
20, 2012 through November 20, 2018.
V. Collection of Information
Requirements
This document does not impose
information collection and
recordkeeping requirements.
Consequently, it need not be reviewed
by the Office of Management and
Budget under the authority of the
Paperwork Reduction Act of 1995 (44
U.S.C. 35).
VI. Regulatory Impact Statement
In accordance with the provisions of
Executive Order 12866, this proposed
notice was not reviewed by the Office of
Management and Budget.
tkelley on DSK3SPTVN1PROD with NOTICES
(Catalog of Federal Domestic Assistance
Program No. 93.778, Medical Assistance
Program; No. 93.773 Medicare—Hospital
Insurance Program; and No. 93.774,
Medicare—Supplementary Medical
Insurance Program)
Dated: September 10, 2012.
Marilyn Tavenner,
Acting Administrator, Centers for Medicare
& Medicaid Services.
[FR Doc. 2012–25467 Filed 10–18–12; 8:45 am]
BILLING CODE 4120–01–P
VerDate Mar<15>2010
16:06 Oct 18, 2012
Jkt 229001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2012–N–0001]
Endocrinologic and Metabolic Drugs
Advisory Committee; Amendment of
Notice
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug Administration
(FDA) is announcing an amendment to
the notice of meeting of the
Endocrinologic and Metabolic Drugs
Advisory Committee. This meeting was
announced in the Federal Register of
October 10, 2012 (77 FR 61609). The
amendment is being made to reflect a
change in the Location and Procedure
portions of the document. There are no
other changes.
FOR FURTHER INFORMATION CONTACT: Paul
Tran, Center for Drug Evaluation and
Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 31, Rm. 2417, Silver Spring,
MD 20993–0002, 301–796–9001; FAX:
301–847–8533, email:
EMDAC@fda.hhs.gov, or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area), and follow the
prompts to the desired center or product
area. Please call the Information Line for
up-to-date information on this meeting.
SUPPLEMENTARY INFORMATION: In the
Federal Register of October 10, 2012,
FDA announced that a meeting of the
Endocrinologic and Metabolic Drugs
Advisory Committee would be held on
November 8, 2012. On page 61609, in
the second column, the Location portion
of the document is changed to read as
follows:
Location: FDA White Oak Campus,
10903 New Hampshire Ave., Building
31 Conference Center, the Great Room,
(Rm. 1503), Silver Spring, MD 20993–
0002. Information regarding special
accommodations due to a disability,
visitor parking, and transportation may
be accessed at: https://www.fda.gov/
AdvisoryCommittees/default.htm; under
the heading ‘‘Resources for You,’’ click
on ‘‘Public Meetings at the FDA White
Oak Campus.’’ Please note that visitors
to the White Oak Campus must enter
through Building 1.
On page 61609, in the third column,
the Procedure portion of the document
is changed to read as follows:
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
before the committee. Written
submissions may be made to the contact
person on or before November 2, 2012.
Oral presentations from the public will
be scheduled between approximately 1
p.m. and 2 p.m. Those individuals
interested in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before October
25, 2012. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by October 26, 2012.
This notice is issued under the
Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14,
relating to the advisory committees.
Dated: October 15, 2012.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2012–25741 Filed 10–18–12; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2012–N–0001]
Nonprescription Drugs Advisory
Committee; Amendment of Notice
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug Administration
(FDA) is announcing an amendment to
the notice of meeting of the
Nonprescription Drugs Advisory
Committee. This meeting was
announced in the Federal Register of
August 30, 2012 (77 FR 52743). The
amendment is being made to reflect a
change in the Location and Contact
Person portions of the document. There
are no other changes.
FOR FURTHER INFORMATION CONTACT:
Minh Doan, Center for Drug Evaluation
and Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Building 31, Rm. 2417, Silver
Spring, MD 20993–0002, 301–796–9001,
E:\FR\FM\19OCN1.SGM
19OCN1
]]>Agencies
[Federal Register Volume 77, Number 203 (Friday, October 19, 2012)]
[Notices]
[Page 64346]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-25741]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2012-N-0001]
Endocrinologic and Metabolic Drugs Advisory Committee; Amendment
of Notice
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
The Food and Drug Administration (FDA) is announcing an amendment
to the notice of meeting of the Endocrinologic and Metabolic Drugs
Advisory Committee. This meeting was announced in the Federal Register
of October 10, 2012 (77 FR 61609). The amendment is being made to
reflect a change in the Location and Procedure portions of the
document. There are no other changes.
FOR FURTHER INFORMATION CONTACT: Paul Tran, Center for Drug Evaluation
and Research, Food and Drug Administration, 10903 New Hampshire Ave.,
Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001; FAX:
301-847-8533, email: EMDAC@fda.hhs.gov, or FDA Advisory Committee
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC
area), and follow the prompts to the desired center or product area.
Please call the Information Line for up-to-date information on this
meeting.
SUPPLEMENTARY INFORMATION: In the Federal Register of October 10,
2012, FDA announced that a meeting of the Endocrinologic and Metabolic
Drugs Advisory Committee would be held on November 8, 2012. On page
61609, in the second column, the Location portion of the document is
changed to read as follows:
Location: FDA White Oak Campus, 10903 New Hampshire Ave., Building
31 Conference Center, the Great Room, (Rm. 1503), Silver Spring, MD
20993-0002. Information regarding special accommodations due to a
disability, visitor parking, and transportation may be accessed at:
https://www.fda.gov/AdvisoryCommittees/default.htm; under the heading
``Resources for You,'' click on ``Public Meetings at the FDA White Oak
Campus.'' Please note that visitors to the White Oak Campus must enter
through Building 1.
On page 61609, in the third column, the Procedure portion of the
document is changed to read as follows:
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before
November 2, 2012. Oral presentations from the public will be scheduled
between approximately 1 p.m. and 2 p.m. Those individuals interested in
making formal oral presentations should notify the contact person and
submit a brief statement of the general nature of the evidence or
arguments they wish to present, the names and addresses of proposed
participants, and an indication of the approximate time requested to
make their presentation on or before October 25, 2012. Time allotted
for each presentation may be limited. If the number of registrants
requesting to speak is greater than can be reasonably accommodated
during the scheduled open public hearing session, FDA may conduct a
lottery to determine the speakers for the scheduled open public hearing
session. The contact person will notify interested persons regarding
their request to speak by October 26, 2012.
This notice is issued under the Federal Advisory Committee Act (5
U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.
Dated: October 15, 2012.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2012-25741 Filed 10-18-12; 8:45 am]
BILLING CODE 4160-01-P
